Capsugel announced that it has completed construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its site in Bend, Ore. The completion represents the final phase of a two-year, $25 million investment....
Ritter Pharmaceuticals, Inc., a pharmaceutical company developing novel therapeutic products...
Cutting-edge new research by KellySciPub indicates that the core personalized medicine market...
In recent news, Allergan will be purchasing Kythera Biopharmaceuticals for $2.1 billion. With...
In my view, the market is set to crash at a certain point in the future. The reason? If the FED raises interest rates, then the value of stocks are due to fall. That's mainly because the discount factor employed as the denominator of the future free cash flows ...
NanoSphere Health Sciences is the first and only patent-pending nanoparticle delivery system for medical and recreational cannabis.
During the first 11 months of 2014, the industry saw $15.3 billion in venture capital compared to $11.5 billion in the first 11 months of 2013.
“The microchip-based implant is truly at the intersection of digital technology and medicine and the future of drug delivery for patients who cannot tolerate needles,” stated Michael Hayden, MD, PhD, Teva’s President of Global R&D and Chief Scientific Officer.
Pursuant to the agreement, Arrowhead will acquire all shares of BTMI from the BTMI shareholders in exchange for 41.5 million common shares of Arrowhead.
While the pancreatic cancer treatment pipeline contains 447 therapeutics in active development across all phases, compared to 209 currently-marketed products, almost 75 percent of therapies are in Phase I or earlier.
Methamphetamine is a highly addictive drug and its production can be highly flammable.
The antipsychotic medication for treatment of depression, bipolar disorder and schizophrenia totaled $7.2 billion in sales between June 2013 and June 2014.
A drug manufacturer is asking the Mississippi Supreme Court to reverse a $38.2 million judgment for the state in a Medicaid drug-pricing lawsuit.
Greengro was recently featured on Forbes list of "hottest marijuana companies" and continues to gain momentum.
The acquisition further diversifies Tribute's product portfolio in Canada through the addition of 13 marketed and two pipeline products.
Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".
The June Kaiser Health Tracking Poll found that nearly three-quarters of respondents believed prescription drug costs are unreasonable, and that of those participants, 76 percent believed drug companies set their prices too high.
Prescription drug sales are forecasted to grow nearly 5% annually over the next five years.
One driver for the company's success is the increased emphasis on strategic partnerships with manufacturers.
Deloitte's report suggests that biopharmaceutical companies could have greater success if they collaborate with other organizations — even competitors — as part of an open innovation approach to research and development.
The combination of Allergan and Actavis created one of the world's top 10 pharmaceutical companies by revenue and a leader in a new industry model.
Target will sell its pharmacy and clinic businesses to the drugstore chain for about $1.9 billion in a deal that combines the resources of two retailers seeking to polish their health care reputations.
The plans include the construction of a new 30,000 square foot, state-of-the-art, fully GMP-compliant cleanroom facility.
Walgreens Boots Alliance, Inc. is recalling a line of women's multivitamins because the packaging is not child-resistant.
ITP affects as many as 5 in 100,000 children each year and is characterized by a low platelet count.
Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.
Carna Biosciences today announced a worldwide licensing agreement with Janssen Biotech to further develop and commercialize compounds from one of Carna Bioscience’s small molecule protein kinase inhibitor programs.
"I have been involved in the pro-life movement for well over 20 years, and I'm not aware of a situation like this ever," said Genevieve Wilson, of Georgia Right to Life.
- Page 1